Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 11, 2012, Pages 1638-1647

  Wang, Shixia ^a   Kishko, Michael ^a   Wan, Shengqin ^a   Wang, Yan ^a   Brewster, Frank ^a   Gray, Glenda E ^b   Violari, Avye ^b   Sullivan, John L ^a   Somasundaran, Mohan ^a   Luzuriaga, Katherine ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antibody; DNA protein boost vaccination; HIV 1; Immunogenicity; Mother to child transmission

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PILOT STUDY; RABBIT; VERTICAL TRANSMISSION; VIRUS GENE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANTIBODY; DNA-PROTEIN BOOST VACCINATION; HIV-1; IMMUNOGENICITY; MOTHER-TO-CHILD TRANSMISSION;

AIDS VACCINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEUTRALIZATION TESTS;

EID: 84869802293     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22414     Document Type: Article

References (40)

1. UNAIDS Report on the Global AIDS Epidemic. 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS). http://wwwunaidsorg/globalreport/defaulthtm.
2. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005; 308:1582- 3; PMID:15947174; http://dx.doi.org/10.1126/science.1112489.
3. Luzuriaga K, Sullivan JL. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev 2002; 4:21-6; PMID:11998780.
4. Ahmad N, Baroudy BM, Baker RC, Chappey C. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995; 69:1001-12; PMID:7815476.
5. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-43; PMID:15464184; http://dx.doi.org/10.1016/S0140-6736(04)17140-7.
6. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, et al.; CHAVI Clinical Core B. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-72; PMID:19487423; http://dx.doi.org/10. 1084/jem.20090365.
7. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7; PMID:18490657; http://dx.doi.org/10.1073/pnas.0802203105.
8. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-70; PMID:18256145; http://dx.doi.org/10.1128/JVI.02660-07.
9. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67:3345-56; PMID:8497055.
10. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-81; PMID:8356453; http://dx.doi.org/10.1126/science.8356453.
11. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255:1134-7; PMID:1546316; http://dx.doi.org/ 10.1126/science.1546316.
12. Dickover RE, Garratty EM, Plaeger S, Bryson YJ. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001; 75:2194-203; PMID:11160723; http://dx.doi.org/10.1128/JVI.75.5.2194-2203.2001.
13. Zhang H, Hoffmann F, He J, He X, Kankasa C, West JT, et al. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006; 3:73; PMID:17054795; http://dx.doi.org/10.1186/1742-4690-3-73.
14. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80:835-44; PMID:16378985; http://dx.doi.org/10.1128/JVI.80.2.835-844.2006.
15. Doms RW. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Topics in HIV medicine: a publication of the International AIDS Society, USA 2004; 12:100-3.
16. Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K. Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology 2011; 8:67; PMID:21843318; http://dx.doi.org/10.1186/1742-4690-8- 67.
17. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005; 79:7933-7; PMID:15919951; http://dx.doi.org/10.1128/JVI.79.12.7933-7937.2005.
18. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-57; PMID:18724414; http://dx.doi.org/10.1016/j.vaccine.2007.12.060.
19. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006; 350:34-47; PMID:16616287; http://dx.doi.org/10.1016/ j.virol.2006.02.032.
20. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008; 82:7369-78; PMID:18495775; http://dx.doi.org/10.1128/JVI.00562-08.
21. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010; 28:2999-3007; PMID:20170767; http://dx.doi.org/10.1016/j.vaccine.2010.02.006.
22. Montefiori DC. (2004) Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current Protocols in Immunology, (Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, and R. Coico, eds.), John Wiley & Sons, 12.11.1-12.11.15.
23. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-52; PMID:15542675; http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004.
24. Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006; 80:1680-7; PMID:16439525; http://dx.doi.org/10.1128/JVI.80.4.1680-1687.2006.
25. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-7; PMID:7692082.
26. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 2006; 3:e255; PMID:16834457; http://dx.doi.org/10.1371/journal.pmed.0030255.
27. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76:7293-305; PMID:12072528; http://dx.doi.org/10.1128/JVI.76.14.7293-7305.2002.
28. Bublil EM, Yeger-Azuz S, Gershoni JM. Computational prediction of the cross-reactive neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific for HIV-1 gp120. FASEB J 2006; 20:1762-74; PMID:16940148; http://dx.doi.org/10.1096/fj.05-5509rev.
29. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, et al. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 2008; 5:5; PMID:18205925; http://dx.doi.org/10.1186/1742-4690-5-5.
30. Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, Weng J, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14:151-5; PMID:9462925; http://dx.doi.org/10. 1089/aid.1998.14.151.
31. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25; PMID:16051804; http://dx.doi.org/10.1128/ JVI.79.16.10108-10125.2005.
32. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, et al. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol 2011; 85:4927-36; PMID:21411542; http://dx.doi.org/10.1128/JVI.00081-11.
33. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80:11776-90; PMID:16971434; http://dx.doi.org/10.1128/JVI.01730-06.
34. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010; 84:1439-52; PMID:19939925; http://dx.doi.org/10.1128/JVI.02108-09.
35. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-12; PMID:12646921; http://dx.doi.org/10.1038/nature01470.
36. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996; 70:1651-67; PMID:8627686.
37. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al.; South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-35; PMID:12599045; http://dx.doi.org/10.1086/367898.
38. Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. Methods Mol Med 2000; 29:355-74; PMID:21374335.
39. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006; 24:4531-40; PMID:16140431; http://dx.doi.org/10.1016/j.vaccine.2005.08. 023.
40. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962-9; PMID:15529261; http://dx.doi.org/10.1086/425518.